OncoPrecision

About OncoPrecision

OncoPrecision is a precision oncology company engineering first-in-class antibody-drug conjugates (ADCs) and bispecific antibodies for hard-to-treat cancers. Our approach begins with patients. We build large-scale patient-derived biology datasets and apply AI-enhanced discovery to identify the targets and mechanisms with the greatest potential to change outcomes — then engineer therapeutics purpose-built around those insights. Our lead program, ONC001, is a first-in-class CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages, with lead indications in monocytic AML and CMML and an expanding strategy into solid tumors. ONC001 is currently advancing through IND-enabling studies. Built on our Patient Micro-Avatar (PMA) platform, OncoPrecision is advancing a pipeline designed to move faster and fail less across hematologic malignancies and solid tumors.